Scholarlink

<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, and it can progress to cirrhosis and hepatocellular carcinoma (HCC). Genetic susceptibility, the gut microbiota, changes in hepatic metabolic pathways, the regulation of lipid metabolism pathways, cellular interactions in the liver, and epigenetic modifications all significantly contribute to MASLD pathogenesis. Recently, epigenetic changes involved in the development and occurrence of MASLD have garnered increasing attention. However, current epigenetic research predominantly focuses on the serum or liver at the whole-tissue level. Consequently, the epigenetic regulation within specific liver cell types, particularly hepatocytes, remains unclear, and its precise mechanisms are not fully understood. This article discusses in detail the specific epigenetic regulatory mechanism of hepatocytes during the occurrence of MASLD, as well as possible therapeutic targets and therapies for these modifications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of hepatocyte epigenetics in the pathogenesis of metabolic dysfunction-associated steatotic liver disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Guangqi Zhu,
  • Qianwen Zhao,
  • Jinqiu Ran,
  • Huan Zhang,
  • Shengxia Yin,
  • Rahma Issa,
  • Junping Shi,
  • Chao Wu,
  • Jie Li

摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, and it can progress to cirrhosis and hepatocellular carcinoma (HCC). Genetic susceptibility, the gut microbiota, changes in hepatic metabolic pathways, the regulation of lipid metabolism pathways, cellular interactions in the liver, and epigenetic modifications all significantly contribute to MASLD pathogenesis. Recently, epigenetic changes involved in the development and occurrence of MASLD have garnered increasing attention. However, current epigenetic research predominantly focuses on the serum or liver at the whole-tissue level. Consequently, the epigenetic regulation within specific liver cell types, particularly hepatocytes, remains unclear, and its precise mechanisms are not fully understood. This article discusses in detail the specific epigenetic regulatory mechanism of hepatocytes during the occurrence of MASLD, as well as possible therapeutic targets and therapies for these modifications.